Seres Therapeutics Inc (MCRB)

07:26 AM

Is Seres Therapeutics Inc. a good long term investmentOutstanding investment returns - PrintWeekIndia

07:26 AM

06:07 AM

What drives Seres Therapeutics Inc. stock priceBreakthrough capital growth - jammulinksnews.com

06:07 AM

11:02 AM

Seres Therapeutics Inc. Stock Analysis and ForecastTremendous return on equity - Autocar Professional

11:02 AM

09:57 AM

individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week - simplywall.st

09:57 AM

Jul 19, 2025

What analysts say about Seres Therapeutics Inc. stockDynamic investment opportunities - jammulinksnews.com

Jul 19, 2025

Jul 18, 2025

what makes seres therapeutics inc. stock price move sharplyChart Breakout Alert - Newser

Jul 18, 2025

Jul 18, 2025

How high can Seres Therapeutics Inc. stock price go in 2025Protected Capital Trading Plan - Newser

Jul 18, 2025

Jul 15, 2025

What makes Seres Therapeutics Inc. stock price move sharplyFree Trading Group - Newser

Jul 15, 2025

Jul 15, 2025

How Seres Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser

Jul 15, 2025

Jul 15, 2025

Why Seres Therapeutics Inc. stock attracts strong analyst attentionFree Smart Money Group - Newser

Jul 15, 2025

Jul 14, 2025

Seres Therapeutics Soars 21%—What’s Fueling the Biotech Breakout? - AInvest

Jul 14, 2025

Jul 01, 2025

5 Best Microbiome Companies (July 2025) - Securities.io

Jul 01, 2025

Jun 30, 2025

Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell 3000E Index - MarketScreener

Jun 30, 2025

Jun 30, 2025

Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell Microcap Growth Index - MarketScreener

Jun 30, 2025

Jun 25, 2025

Seres Therapeutics May 2025 slides: SER-155 shows 77% infection reduction in transplant patients - Investing.com

Jun 25, 2025

Jun 12, 2025

FMR LLC Reduces Stake in Seres Therapeutics Inc: A Strategic Rea - GuruFocus

Jun 12, 2025

Jun 02, 2025

Denodo University Challenge Now Open: Data and AI for Real-World Impact - GlobeNewswire Inc.

Jun 02, 2025

May 28, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World

May 28, 2025

May 27, 2025

Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa

May 27, 2025

May 27, 2025

Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus

May 27, 2025

May 27, 2025

Seres Therapeutics reports promising biomarker data - Investing.com

May 27, 2025

May 27, 2025

Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq

May 27, 2025

May 27, 2025

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting - The Manila Times

May 27, 2025

May 27, 2025

Breakthrough: Seres Therapy Cuts Deadly Infection Risk by 77% in Cancer Transplant Patients, ASCO Data Shows - Stock Titan

May 27, 2025

May 23, 2025

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

May 23, 2025

May 17, 2025

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - Defense World

May 17, 2025

May 16, 2025

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade - NewsBreak: Local News & Alerts

May 16, 2025

May 12, 2025

Human Microbiome Market Forecast: Growth Trends, Key Players & - openPR.com

May 12, 2025

May 11, 2025

Seres Therapeutics’ (MCRB) “Neutral” Rating Reiterated at Chardan Capital - Defense World

May 11, 2025

May 09, 2025

StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold - Defense World

May 09, 2025

May 08, 2025

Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com

May 08, 2025

May 08, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025

May 08, 2025

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga

May 08, 2025

May 08, 2025

Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25 - marketscreener.com

May 08, 2025

May 08, 2025

MCRB: Seres Therapeutics' Price Target Raised by Chardan Capital | MCRB Stock News - GuruFocus

May 08, 2025

May 08, 2025

Chardan cuts Seres Therapeutics stock rating to neutral - Investing.com

May 08, 2025

May 08, 2025

Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour

May 08, 2025

May 08, 2025

Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks

May 08, 2025

May 07, 2025

Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks

May 07, 2025

May 07, 2025

Transcript : Seres Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com

May 07, 2025

May 07, 2025

Earnings call transcript: Seres Therapeutics Q1 2025 sees net income boost - Investing.com Nigeria

May 07, 2025